Metalmark Capital up to $50 million investment in Morgenesis
Davis Polk advised Metalmark Capital on its investment of up to $50 million in Orgenesis’s U.S.-based point of care services subsidiary, Morgenesis LLC.
Metalmark Capital is a leading private equity firm that seeks to build long-term value through active and collaborative partnerships with business owners, founders and executives. The firm focuses its investment activity in healthcare, agribusiness and industrials. Metalmark Capital manages funds with $3 billion in aggregate capital commitments.
Orgenesis is a global biotech company working to unlock the full potential of cell and gene therapies in an affordable and accessible format at the point of care.
The Davis Polk corporate team included partner Michael Davis and associates Heather Weigel and Samuel Liebmann. The finance team included partner Hilary Dengel and counsel Welton E. Blount. The intellectual property and technology transactions team included partner David R. Bauer and associate Adrian Rabin. The tax team included partner Ethan R. Goldman. The executive compensation team included partner Adam Kaminsky. Members of the Davis Polk team are based in the New York and Washington DC offices.